Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients

Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable. A total of 139 HIV/TB adults, 101 of whom received a rifampin-containing a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Manosuthi, Weerawat, Sukasem, Chonlaphat, Lueangniyomkul, Aroon, Mankatitham, Wiroj, Thongyen, Supeda, Nilkamhang, Samruay, Manosuthi, Sukanya, Sungkanuparph, Somnuek
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2013
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553682/
https://ncbi.nlm.nih.gov/pubmed/23254426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02023-12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires